8:00 am Registration & Morning Coffee

8:50 am Chairs’ Opening Remarks

Selecting Optimal Models for Determining Your ADC Toxicity Profile

9:00 am Understanding Underlying Mechanisms of Action to Accurately Determine Class Effects of Different Payloads & How They Will Translate

Synopsis

  • Looking into mechanisms of action of different ADCs to determine toxicities
  • Applying this understanding to the development of your ADC candidates
  • Widening your understanding of how your drug will translate to humans in the clinic

9:00 am Development of Acute Rodent Models to Establish Surrogate Endpoints for Clinically Relevant Toxicities

  • Ronnie Yeager Project Director/Toxicologist, Emerging Therapeutic Platforms, Abbvie

Synopsis

  • Delving into acute rodent toxicity model development
  • Looking into corneal toxicity as a case study
  • Understanding liver sinusoidal injury as a clinical toxicity

9:30 am Morning Refreshments & Networking

Synopsis

This session is an opportunity to connect with peers working on ADC drug development and hold in-depth conversations with some of the brightest minds to establish meaningful and lasting relationships.

10:30 am Designing NHP studies to define ADC toxicities that are translatable to the clinic

Synopsis

  • How to use known payload class effects to design an informative NHP safety evaluation
  • Maximizing your toxicology study while reducing NHP use to obtain the most relevant safety information
  • Determining when toxicity is on-target or off-target using dermal toxicity as a case study

11:00 am Choosing the Most Appropriate Models for Your Preclinical ADC Toxicity Study

  • Sylvain Thierry Head of Pharmacology Immuno-Oncology & Targeted Therapies, Mablink

Synopsis

• Deciding the most relevant species based on your target and ADC for toxicity

• Selecting the most appropriate species to conduct your toxicity studies in

• Determining if humanized models are always the most representative choice for safety

11:30 am Lunch & Networking

Informing Clinical Trial Design & Toxicity Monitoring Using Preclinical Data

1:00 pm Evaluating Preclinical Study Findings & Determining Appropriate Outline for Clinical Trial Design to Minimize Toxicity

Synopsis

  • Designing more robust clinical studies with relevant preclinical findings
  • Determining the relevance of preclinical data when translated into a human in the clinic
  • Expecting toxicities more accurately in the clinic based on your preclinical findings

1:30 pm Nonclinical & Clinical Toxicity Assessment of ELU001, a C’Dot Drug Conjugate (CDC) Targeting Folate Receptor Alpha

Synopsis

  • Deep diving into a case study of a C’Dot Drug Conjugate
  • Selecting appropriate models to determine safety profiles
  • Looking at what has been seen in the trial relating to learnings from tox studies

2:00 pm Afternoon Refreshments & Scientific Poster Session

Synopsis

The scientific poster session will serve as the perfect opportunity to showcase your recent work to your peers and allow you to learn and share insights in a relaxed atmosphere.

Mitigating ADC Related Toxicities in the Clinic to Expand Therapeutic Windows

3:00 pm A Case Study on Ocular Toxicities: How to Mitigate a Known Toxicity in the Clinic

  • Grace Lytle Executive Ocular Medical Director, ImmunoGen

Synopsis

  • Underlining the mechanisms of action and how ocular toxicity comes about with ADC treatments
  • Discussing how the mitigation and management strategies for ocular toxicity with developed
  • Successes of mitigating this common toxicity and how it has allowed increases in dosage and subsequently efficacy

3:30 pm Understanding Toxicities Associated with Developing ADCs for Gynaecological Cancers: A Case Study on Mirvetuximab Soravtansine

Synopsis

  • Looking into the unique toxicity related challenges when developing ADCs for Gynaecological disorders
  • Delving into the case study of Mirvetuximab Soravtansine for treating ovarian cancer
  • Learning how to manage these toxicities in the clinic

4:00 pm End of Scientific Program Day One